Clinical Scorecard: Addressing Polycystic Ovary Syndrome to Mitigate Cardiovascular Disease Risk

At a Glance

Key Highlights

• PCOS increases cardiovascular disease (CVD) risk by 77%, with over two-fold increased risk of coronary artery disease and myocardial infarction, independent of genetic risk.
• Non-obese women with PCOS have significant CVD risk often underestimated and conventional therapies show no positive impact on CVD outcomes in this group.
• Alternative therapeutic approaches including estradiol and progesterone supplementation, GLP-1 receptor agonists, and lifestyle interventions are proposed to improve cardiovascular outcomes.

Guideline-Based Recommendations

Diagnosis

• PCOS is a diagnosis of exclusion; rule out other causes of androgen excess such as Cushing’s syndrome, hyperprolactinaemia, late onset adrenal hyperplasia, adrenal and ovarian tumors, ovarian hyperthecosis, and thyroid disease.
• Careful evaluation is needed to differentiate PCOS from obesity-related androgen excess.

Management

• Conventional therapies including hormonal contraceptives, metformin, and anti-androgens have not demonstrated positive impact on CVD outcomes in PCOS.
• Consider prescriptive use of supplemental continuous estradiol and cyclic progesterone to address hormonal imbalances and reduce systemic inflammation.
• Use GLP-1 receptor agonists in conjunction with lifestyle programs to improve metabolic function and reduce cardiovascular risk.
• Omega-3 fatty acids may be used to reduce risk of myocardial infarction, including fatal events.

Monitoring & Follow-up

• Long-term cardiovascular risk assessment in women with PCOS, including non-obese individuals.
• Monitor hormonal levels including follicle-stimulating hormone, luteinizing hormone, estradiol, and testosterone.
• Evaluate metabolic parameters such as insulin resistance and lipid profiles.

Risks

• Misdiagnosis of PCOS in obese women due to obesity mimicking PCOS symptoms.
• Increased risk of coronary artery disease, myocardial infarction, and stroke in PCOS patients.
• Low estradiol levels as a risk factor for cardiovascular events.

Patient & Prescribing Data

Women with PCOS, including non-obese and obese subgroups

Conventional treatments show limited efficacy in reducing cardiovascular events; emerging therapies such as estradiol/progesterone supplementation and GLP-1 receptor agonists combined with lifestyle modifications may offer improved cardiovascular protection.

Clinical Best Practices

• Perform thorough differential diagnosis to confirm PCOS and exclude other causes of androgen excess.
• Recognize and address cardiovascular risk in non-obese women with PCOS, a frequently underappreciated group.
• Implement hormonal supplementation with estradiol and progesterone to correct endocrine imbalances and reduce inflammation.
• Incorporate GLP-1 receptor agonists alongside lifestyle interventions targeting nutrition, gut microbiome, autonomic balance, circadian rhythm, fitness, sleep, and mood.
• Consider omega-3 fatty acid supplementation to reduce myocardial infarction risk.

References

• Nonobese young females with polycystic ovary syndrome are at high risk for long-term cardiovascular disease, Zhao et al.